AbbVie Third-Quarter Revenue Hits $17.4 Billion as Skyrizi Sales Jump 22.7%; Full-Year Guidance Raised and 2027 Dividend Lifted 5.2%
US drugmaker AbbVie reported third-quarter results on October 30 for the quarter ended September 30, 2026: worldwide net revenues were $17.404 billion, an increase of 10.3 percent on a reported basis, or 10.5 percent on an operational basis. Diluted earnings per share were $2.37 on a GAAP basis and $3.82 on an adjusted basis, both up more than 100 percent from a year earlier, including an unfavorable impact of $0.11 per share related to acquired in-process research and development (IPR&D) and milestones expense.
According to Reuters, adjusted earnings of $3.82 per share beat analysts' expectations of $3.75, and revenue of $17.40 billion topped estimates of $17.31 billion. AbbVie shares have risen about 27 percent so far this year and closed at a record high of $290.79 on Thursday.
The immunology portfolio did the heavy lifting, with global net revenues of $9.165 billion, up 16.3 percent. Skyrizi recorded sales of $5.776 billion, up 22.7 percent and ahead of the $5.75 billion expected by analysts in data compiled by LSEG, while Rinvoq generated $2.706 billion, up 23.9 percent. Global Humira net revenues fell 31.2 percent to $683 million.
The neuroscience portfolio grew 19.4 percent to $3.389 billion, helped by Botox Therapeutic at $1.080 billion and Vraylar at $1.068 billion. Oncology revenues were $1.696 billion, up 0.8 percent, while the aesthetics portfolio eased 1.4 percent to $1.176 billion.
AbbVie raised its full-year 2026 adjusted diluted EPS guidance from $13.76-$13.96 to $13.95-$13.99, including an unfavorable impact of $0.69 per share from acquired IPR&D and milestones expense incurred year to date through the third quarter. The company also announced a 5.2 percent dividend increase for 2027, beginning with the dividend payable in February 2027.
AbbVie confirmed it has completed its acquisition of Apogee Therapeutics, adding assets including zumilokibart, a late-stage antibody for atopic dermatitis, and APG273 for asthma to its immunology pipeline. Reuters previously reported the deal was valued at $10.9 billion and agreed in June.
"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert A. Michael, chairman and chief executive officer. "We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics." The full release is available from AbbVie, Reports Third-Quarter 2026 Financial Results.
Source: GSM · USA (original Chinese edition)
Photo: 图：艾伯维（AbbVie）位于伊利诺伊州 North Chicago 的总部大楼（资料图）。LittleT889 摄，CC BY 4.0，经 Wikimedia Commons。 / AbbVie headquarters in North Chicago, Illinois (file photo). Photo by LittleT889, CC BY 4.0, via Wikimedia Commons.
